Three-year overall survival update from the PACIFIC trial.

Jhanelle E. Gray,A. Villegas,Davey B. Daniel,D. Vicente,S. Murakami,Rina Hui,Takayasu Kurata,Alberto Chiappori,Ki Hyeong Lee,Byoung Chul Cho,David Planchard,Luis Paz-Ares,Corinne Faivre-Finn,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu,Scott Antonia

Three-year overall survival update from the PACIFIC trial.

2019

8526Background: In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versu...

Keywords:

Chemoradiotherapy
Physical therapy
Durvalumab
Oncology
Stage III NSCLC
Internal medicine
Medicine
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations